European stocks rise as Novo Nordisk lifts healthcare on Wegovy data

European shares edged higher on Monday, primarily driven by strong performance in healthcare stocks after Novo Nordisk surged 3.1% on data showing its weight-loss drug Wegovy cut cardiovascular event risk by 57% versus Eli Lilly's rivals in a real-world comparison. Defence stocks also advanced 1.2%, with BAE Systems up 2%, following Norway's selection of the UK for a £10 billion frigate acquisition, while a U.S. appeals court ruled most Trump-era tariffs illegal, though they remain effective until mid-October.

Analysis

The pan-European STOXX 600 advanced 0.26% to 551.56, with gains concentrated in the healthcare and defence sectors on a day of light trading due to a U.S. holiday. The primary catalyst was a 3.1% surge in Novo Nordisk shares after the company released real-world data showing its weight-loss drug Wegovy reduced the risk of heart attack, stroke, or cardiovascular death by 57% compared to rival treatments from Eli Lilly. This data provides a significant competitive advantage for Novo Nordisk in the high-growth obesity drug market and directly pressured Eli Lilly's valuation. Concurrently, a 1.2% rise in the defence sector was led by BAE Systems, which climbed 2% after Norway selected the UK as its strategic partner for a new frigate acquisition valued at approximately £10 billion, signaling a material enhancement to BAE's order book. Externally, a U.S. appeals court ruling deemed most Trump-era tariffs illegal but allowed them to remain in place until mid-October, introducing a deferred source of potential market volatility for transatlantic trade.

Key Decisions for Investors

• The compelling cardiovascular data for Novo Nordisk's Wegovy strengthens its competitive moat against Eli Lilly, warranting a potential overweight position in NVO and a re-evaluation of exposure to LLY.
• BAE Systems' selection for the £10 billion Norwegian frigate program provides significant long-term revenue visibility, reinforcing a bullish thesis for the stock and the European defence sector.
• Investors with exposure to tariff-sensitive sectors should monitor the U.S. court's tariff ruling, as the mid-October deadline for appeals could introduce significant volatility for impacted European exporters.
• Given the market's advance on light volume, positions should be monitored for potential retracement as fuller-volume trading resumes with the return of U.S. market participants.